FDA Explores NGS for Outbreaks but Says Technology Not Yet Cost-Effective for Routine Use

As next-gen sequencing "continues to improve both in terms of time for analyses as well as cost … we anticipate that there will be a role for whole-genome sequencing during certain foodborne outbreaks," an FDA official said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.